Key facts
- This page summarizes John M. Evans's Form 4 filing for Beam Therapeutics Inc. (BEAM).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 04 Apr 2022, 20:27.
John M. Evans - 31 Mar 2022 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)
- Reporting relationship
- CEO, Director
- Issuer ticker
- BEAM
- Reported as of
- 31 Mar 2022
- Net transaction value
- -$370,088
- SEC form
- 4
- Accepted by SEC
- 04 Apr 2022, 20:27:59 UTC
- Prior SEC filing
- 02 Feb 2022
- Next SEC filing
- 02 May 2022
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Christine Bellon, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
John M. Evans filed Form 4 for Beam Therapeutics Inc. (BEAM) on 04 Apr 2022.
Change
- Previous filing in this sequence was filed on 02 Feb 2022.
- Current net transaction value: -$370,088.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BEAM
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +56,250
- Change %
- +5.4%
- Price
- $0.000000
- Shares after
- 1,095,331
- Date
- 31 Mar 2022
- Ownership
- Direct
- Footnotes
- F1, F2
BEAM
transaction
Common Stock
Sale
- Transaction value
- -$370,088
- Shares
- -6,261
- Change %
- -0.57%
- Price
- $59.11
- Shares after
- 1,089,070
- Date
- 31 Mar 2022
- Ownership
- Direct
- Footnotes
- F3
BEAM
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 163,000
- Date
- 31 Mar 2022
- Ownership
- By John M. Evans, III 2018 Irrevocable Trust
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with the Company through each vesting date.
Footnote F2
Includes 256 shares acquired under the Issuer's employee stock purchase plan on March 31, 2022.
Footnote F3
These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain RSUs.